Rheumatology

AMCP Posters Demonstrate Value of Biosimilars

April 20th 2020

By Skylar Jeremias

Posters presented at the Academy of Managed Care Pharmacy (AMCP) eLearning Days meeting this week from April 20 to 24 reveal important data on biosimilar utilization management, switching, and affordability.

American Rheumatology Network Promotes a Biosimilar Pathway

April 19th 2020

By Skylar Jeremias

Article

A pathway model that incorporated use of biosimilars has shown great promise, according to Colin C. Edgerton, MD, executive chairman of the American Rheumatology Network.

Patient Awareness of Biosimilars Is Poor in Australia, Study Says

April 17th 2020

By Deana Ferreri, PhD

Article

Patients in an Australian clinic were generally open to using biosimilars but knew little about them, according to a recent study.

AbbVie Patents Are Costly for Healthcare Consumers

April 11th 2020

By Tony Hagen

Article

The Danish medical system saved 82.8% on adalimumab by switching almost all patients from the reference product to biosimilars, but such a benefit for the US healthcare system may not be possible, according to a new study.

Pfizer Gains European Commission Approval for Rituximab Biosimilar

April 2nd 2020

By The Center for Biosimilars

Article

Following close on the heels of its US approval for Ruxience (rituximab), Pfizer has gained the European Commission nod and aims to launch in coming months.

Study: Employers Can Save With Biosimilars

April 1st 2020

By Skylar Jeremias

Article

Self-insured companies could have saved $407 million to $1.4 billion in 2018 had they switched completely from reference biologics infliximab and filgrastim to biosimilars.

Etanercept Biosimilar Is Recommended for Use in European Union

March 27th 2020

By The Center for Biosimilars

Article

Mylan and Lupin have gained the necessary recommendation to begin marketing their etanercept biosimilar in Europe.

Alvotech Hf and DKSH Announce Plans to Bring an Adalimumab Biosimilar to Market

March 26th 2020

By The Center for Biosimilars

Article

Alvotech Hf and DSH hope to get an adalimumab biosimilar approved in the United States, Europe, and selected Southeast Asia markets.

ACR: Prior Authorization Requirements Must Be Reduced

March 21st 2020

By Skylar Jeremias

Article

The American College of Rheumatology (ACR) has issued a list of recommendations for streamlining prior authorization to eliminate redundancy and improve access for patients.

Nocebo Effect Is Difficult to Diagnose in Patients Switched to Biosimilars

March 17th 2020

By Skylar Jeremias

Article

In inflammatory rheumatic diseases, the nocebo effect may account for a portion of treatment failures among patients who were placed on biosimilars; however, discontinuations due to the nocebo effect can be difficult to diagnose due to the absence of diagnostic criteria, differences in pathologic backgrounds for each disorder, and the absence of specific neurochemical and neuroimaging studies, investigators found.